On Christmas Day 2024, Elon Musk posted a photograph of himself in a Santa costume with the caption 'Ozempic Santa,' then followed up with a correction — 'Technically, Mounjaro' — clarifying that the specific GLP-1 receptor agonist he was using was tirzepatide (Mounjaro) rather than semaglutide (Ozempic).^[1] He had previously credited a combination of 'Fasting' and 'Wegovy' for earlier weight changes he had discussed publicly.^[1]

What he said about tolerability and access

In the follow-up posts and the interviews that clustered around them, Musk offered two claims worth pulling out. First, he described Mounjaro as producing fewer side effects for him than the GLP-1 he had previously used — a personal report, not a comparative trial.^[1] Second, and more consequentially for policy, he argued publicly for making 'GLP inhibitors super low cost to the public,' framing the drugs as an infrastructure-scale intervention rather than a boutique one.^[1]

The access argument he made — that effective weight-management pharmacotherapy should not be gated by price — is a policy claim currently being made by health economists, public-health officials, and payer coalitions in various forms. It intersects with the ongoing debate about drug pricing generally and about how the U.S. health system should absorb a class of medications with genuinely large addressable populations.

Disclosure and how it differs from the other profiles

Unlike the Serena Williams and Shaquille O'Neal profiles elsewhere in this section, Musk's disclosures were not, so far as the public record shows, part of a paid commercial partnership.^[1] They were personal social-media posts by an unusually high-reach public figure. That distinction matters when weighing how the disclosures should be read: the Williams and O'Neal stories carry a paid-partnership disclosure requirement that the Musk posts do not, and the Musk posts in turn come without the editorial guardrails a paid campaign would impose.

What is and is not in evidence

Two boundary conditions belong on the record. Side-effect experiences vary considerably between individuals and between specific GLP-1 receptor agonists, and any single user's account — including Musk's — is a data point rather than a comparative trial result. And the access argument is a policy claim, not a medical claim; it is entirely coherent to agree with the policy framing while withholding judgment on any specific individual's clinical decisions.

The regulatory frame that applies

Both drugs Musk named — Ozempic and Mounjaro — are FDA-approved prescription medications for their approved indications.^[2] They are prescribed and dispensed through the standard pharmacy system, and their labels carry specific warnings and precautions that would apply to any patient starting them. The commentary Musk offered is best read as part of the cultural conversation around the class, not as a source of clinical guidance.